Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.39

€0.39

2.390%
0.009
2.390%
-

-

 
17:08 / Tradegate WKN: A3D1K3 / Name: Bionxt Solutions / Stock / Small Cap /

Bionxt Solutions Inc. Stock

Bionxt Solutions Inc. gained 2.390% today.
So far the community has only identified positive things for Bionxt Solutions Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Bionxt Solutions Inc. in the next few years

Pros
?
S********** s********
?
B****
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'

News

BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis
BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis

VANCOUVER, BC / ACCESS Newswire / February 17, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug

BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery
BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery

VANCOUVER, BC / ACCESS Newswire / February 5, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug

BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion
BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion

VANCOUVER, BC / ACCESS Newswire / January 26, 2026 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug